Role of Genetics

The genetic mutation behind Duchenne.

Understanding the cause of Duchenne begins with understanding the role of proteins and genes in how our bodies function.


Proteins are necessary for many important functions in the body, such as digesting our food, growing our bones, or—in the case of the protein called dystrophin—helping our muscles work properly.

Genes are made up of segments, called “exons,” that tell our cells which proteins to make. The dystrophin gene is made up of 79 exons that, when linked together, form the instructions for making dystrophin.

Image
6-2-hero-liam.

Meet Liam, age 19
Deletion of exons 48-50


What is a genetic mutation?

A mutation is a change in a person's DNA. Mutations range in size from a small (a single rung on a ladder) to a large segment of DNA. Every mutation causes a different effect on our bodies. A mutation on the dystrophin gene means dystrophin is not produced—resulting in Duchenne.

3 common types of mutations.

Large deletions

One or more exons are missing

72%

of people with Duchenne

13%

About 13% of people diagnosed with Duchenne have the genetic mutation that is amenable to EXONDYS 51. Learn what this means.

Large duplications

One or more exons are duplicated

7%

of people with Duchenne
(Not treatable with EXONDYS 51)

Other changes

Small deletions or interruptions in the instructions

20%

of people with Duchenne
(Not treatable with EXONDYS 51)

EXONDYS 51 is used to treat Duchenne in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51. EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

The importance of genetic testing.

While there is presently no cure for Duchenne, advances in research offer hope. Genetic testing can now pinpoint the specific exons that are missing from the dystrophin gene. That’s why it’s so important for every child living with Duchenne to have a current genetic test—and for parents to understand the results.
 

Your child has a confirmed diagnosis of Duchenne. Have they had a genetic test?
 

No.

 

Image
No

 

 

Now is the time to talk to your child's doctor about testing.
Learn about genetic testing.

 

Yes,

a recent test, but I‘m not sure about the results.

 

Image
Yes1

 

Ask your child’s doctor to review the test to see if the genetic mutation is identified. Learn how to read the test results yourself.

 

Yes,

but it was several years ago.

 

Image
dna

 


Test methods have improved in recent years. Talk to your doctor about a retest to identify the mutation.

 

 

How is a genetic test performed? Getting a genetic test is usually as simple as providing a blood or saliva sample.

1.

To confirm a Duchenne diagnosis

2.

To identify the genetic mutation and explore possible therapy options

3.

To facilitate potential clinical trial participation

4.

To assist with family planning

 

 

Wondering what to expect?

Get insights into the Duchenne diagnostic process.

 

Ready to talk to your child’s doctor?

Create a personalized Doctor Discussion Guide.
 

 

 

Image
Desktop star

Sign up to get updates
from Sarepta.  

Related FAQs

How will I know if my child can be treated with EXONDYS 51?

A genetic test is the only way for your child's doctor to identify your child's mutation and determine if the mutation is amenable to treatment with EXONDYS 51. Learn how genetic mutations are identified.

Is the treatment effective?

Weekly infusions of EXONDYS 51 helped the body make a shorter form of the dystrophin protein in some boys. View the results from clinical studies.

 

EXONDYS 51 is used to treat Duchenne in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51. EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

 

 

WHAT IS EXONDYS 51 (eteplirsen)?

EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51. EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

Read More

IMPORTANT RISK INFORMATION

Allergic reactions, including wheezing, chest pain, cough, rapid heart rate, and hives have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Side effects that happened at least 25% more often in 8 patients treated with EXONDYS 51 by intravenous infusion than in 4 patients treated with an inactive intravenous infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

The most common side effects seen in greater than 10% of patients receiving EXONDYS 51 (N=163) in other clinical trials were headache, cough, rash, and vomiting. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).